Mast Cell Pharmaceuticals

Mast Cell Pharmaceuticals is a clinical-stage biotechnology company based in Raleigh, North Carolina, focused on developing and evaluating therapies for mast cell-mediated and allergic disorders. The company specializes in repurposing small molecule mast cell stabilizers and antihistamines to improve the safety of food allergy immunotherapies and treat eosinophilic gastrointestinal diseases. Its key research programs include the use of ketotifen as a premedication for peanut oral immunotherapy and the combination of famotidine and loratadine for eosinophilic esophagitis. Mast Cell Pharmaceuticals collaborates with leading academic institutions and clinical research organizations to advance its pipeline through Phase 2 clinical trials. The company's approach aims to provide rapid and effective symptomatic relief while mitigating the risks associated with traditional allergy treatments.